"MNK looking to sell its generics business to focus on specialised treatments.
MNK is trying to move in the right direction, instead of following the so-far disastrous decision that Teva took to double down on its generics business."
@stockrock,
Given MNK's levels of indebtedness (~US$6bn of borrowings), it looks more like they are selling off businesses in order to keep their creditors at bay.
As for them "trying to move in the right direction", if you mean that involves partnering with MSB in some form, how do you think they might fund such a move, in the light of their challenged financial position?
Teva shares plummet 21%, page-8
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.28 |
Change
0.000(0.00%) |
Mkt cap ! $1.478B | |||
| Open | High | Low | Value | Volume |
| $1.29 | $1.31 | $1.27 | $969.2K | 753.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 18 | 12283 | $1.28 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.28 | 29239 | 11 |
View Market Depth
| Last trade - 13.03pm 05/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |